Immunome, Inc. (NASDAQ:IMNM) Receives $33.45 Average Target Price from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $33.4545.

Several equities research analysts recently issued reports on IMNM shares. Stephens reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Craig Hallum lifted their price objective on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. HC Wainwright assumed coverage on shares of Immunome in a report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a report on Thursday, January 15th.

Immunome Stock Performance

IMNM stock opened at $24.63 on Wednesday. Immunome has a 1 year low of $7.15 and a 1 year high of $27.65. The company has a fifty day simple moving average of $21.77 and a 200 day simple moving average of $20.20. The firm has a market cap of $2.79 billion, a PE ratio of -10.18 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). As a group, analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Philip Wagenheim sold 36,800 shares of Immunome stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director owned 369,347 shares in the company, valued at $7,560,533.09. This trade represents a 9.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the completion of the transaction, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. This trade represents a 54.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,438 shares of company stock worth $2,964,664 in the last quarter. 7.69% of the stock is currently owned by company insiders.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the last quarter. Vanguard Group Inc. grew its position in Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its position in Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp grew its position in Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.